Paul DeAngelis, Ph.D.
Year 1: 687,609.00 Year 2: 550,002.00
Oklahoma Glyco-manufacturing Facility: Going Global with Next-gen Sugar-based Therapeutics
The project would invest EDGE funding to establish a world-class mid-level capacity glyco-manufacturing facility that will sell a wide variety of sugar materials to the academic research community and medical product manufacturers. Hyalose will form an alliance with Cytovance Biologics to co-develop the scale-up production components to use for sugar-based products as well as develop FDA-approved procedures for documentation.
Hyalose, L.L.C., an Emergent Technologies, Inc. (ETI) Oklahoma City-based portfolio company, is using its $1.23 million endowment from EDGE to build a center for manufacturing hyaluronic acid (HA) and related glycosaminoglycans (GAG’s) products to meet the demands of researchers for larger quantities of HA and heparosan for clinical research. The new Oklahoma Glyco-Manufacturing Center (OGC) will be located in the Presbyterian Health Foundation’s Research Park in Oklahoma City.
With a strong intellectual portfolio (IP) of 35 issued and 49 pending patents, Hyalose’s technology has potential applications in multiple high-yield markets including the $4 billion orthopedic biomaterial market1 and the $4.2 billion medical device coatings market2. Hyalose also provides competitive advantages to a broader market of glycoengineering, including tissue engineering, estimated to be $15 billion per year currently3, and medical device coatings, estimated at $4.2 billion and expected to grow to over $5 billion by 2010.2 As more medical and pharmaceutical uses for HA continue to emerge, the value of the technology continues to increase.
Hyalose Chief Scientist Dr. Paul DeAngelis, who is a professor at the University of Oklahoma Health Sciences Center (OUHSC), will direct the project to create a unique, one-of-a-kind, world class facility meeting U.S. Food and Drug Administration (FDA) requirements. Cytovance Biologics through an alliance agreement will provide the floor space in Building #1 and expert assistance in the design of the center, equipment procurement, installation, commissioning, start-up, and operations.
The technology to produce these unique molecules was discovered at OUHSC, and the current suite of products was developed in the Hyalose laboratory using company funding and an Oklahoma Advanced Research Support (OARS) grant from the Oklahoma Center for Advancement of Science and Technology (OCAST). For the last four years Hyalose has seeded the research community with HA products made in lab-scale batch processes. The community’s recent discoveries in cancer research are resulting in orders for larger quantities with lower unit costs, and the new center will provide the economy of scale necessary to accommodate growth and development in the HA and related research fields.